BofA analyst Allen Lutz raised the firm’s price target on Cencora (COR) to $285 from $270 and keeps a Neutral rating on the shares. The recent introduction of tariffs on China and India, combined with the current administration’s changes to the FDA, could “create a perfect storm leading to generic inflation,” says the analyst, who highlights upside in the case of generic inflation for Cardinal Health (CAH), McKesson (MCK) and Cencora.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $274 from $251 at Wells Fargo
- Cencora’s Mixed Regional Performance and Valuation Concerns Justify Hold Rating
- Cencora’s Strategic Growth and Robust Performance Justify Buy Rating
- Positive Outlook for Cencora Amid Walgreens’ Transition to Private Ownership
- Cencora to Update 2025 Financial Guidance at Conference